These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
183 related articles for article (PubMed ID: 36920334)
1. Evaluation of the in vitro and in vivo effect of liposomal doxorubicin along with oncolytic Newcastle disease virus on 4T1 cell line: Animal preclinical research. Faranoush P; Jahandideh A; Nekouian R; Mortazavi P Vet Med Sci; 2023 May; 9(3):1426-1437. PubMed ID: 36920334 [TBL] [Abstract][Full Text] [Related]
2. Genetic Modification of Oncolytic Newcastle Disease Virus for Cancer Therapy. Cheng X; Wang W; Xu Q; Harper J; Carroll D; Galinski MS; Suzich J; Jin H J Virol; 2016 Jun; 90(11):5343-5352. PubMed ID: 27009956 [TBL] [Abstract][Full Text] [Related]
3. Oncolytic Newcastle disease virus carrying the IL24 gene exerts antitumor effects by inhibiting tumor growth and vascular sprouting. Wu Q; Jin Y; Li S; Guo X; Sun W; Liu J; Li Q; Niu D; Zou Y; Du X; Li Y; Zhao T; Li Z; Li X; Ren G Int Immunopharmacol; 2024 Jul; 136():112305. PubMed ID: 38823178 [TBL] [Abstract][Full Text] [Related]
4. Type I interferon-sensitive recombinant newcastle disease virus for oncolytic virotherapy. Elankumaran S; Chavan V; Qiao D; Shobana R; Moorkanat G; Biswas M; Samal SK J Virol; 2010 Apr; 84(8):3835-44. PubMed ID: 20147405 [TBL] [Abstract][Full Text] [Related]
6. Newcastle disease virus LaSota strain induces apoptosis and activates the TNFα/NF-κB pathway in canine mammary carcinoma cells. Wang J; Li M; Li M Vet Comp Oncol; 2023 Sep; 21(3):520-532. PubMed ID: 37282822 [TBL] [Abstract][Full Text] [Related]
7. Oncolytic Newcastle disease virus expressing a checkpoint inhibitor as a radioenhancing agent for murine melanoma. Vijayakumar G; Palese P; Goff PH EBioMedicine; 2019 Nov; 49():96-105. PubMed ID: 31676387 [TBL] [Abstract][Full Text] [Related]
8. Genetically engineered Newcastle disease virus expressing interleukin-2 and TNF-related apoptosis-inducing ligand for cancer therapy. Bai FL; Yu YH; Tian H; Ren GP; Wang H; Zhou B; Han XH; Yu QZ; Li DS Cancer Biol Ther; 2014 Sep; 15(9):1226-38. PubMed ID: 24971746 [TBL] [Abstract][Full Text] [Related]
9. Design and Production of Newcastle Disease Virus for Intratumoral Immunomodulation. Vijayakumar G; Zamarin D Methods Mol Biol; 2020; 2058():133-154. PubMed ID: 31486036 [TBL] [Abstract][Full Text] [Related]
10. Recombinant oncolytic Newcastle disease virus displays antitumor activities in anaplastic thyroid cancer cells. Jiang K; Song C; Kong L; Hu L; Lin G; Ye T; Yao G; Wang Y; Chen H; Cheng W; Barr MP; Liu Q; Zhang G; Ding C; Meng S BMC Cancer; 2018 Jul; 18(1):746. PubMed ID: 30021550 [TBL] [Abstract][Full Text] [Related]
11. Use of reverse genetics to enhance the oncolytic properties of Newcastle disease virus. Vigil A; Park MS; Martinez O; Chua MA; Xiao S; Cros JF; Martínez-Sobrido L; Woo SL; García-Sastre A Cancer Res; 2007 Sep; 67(17):8285-92. PubMed ID: 17804743 [TBL] [Abstract][Full Text] [Related]
12. Targeting STAT3 enhances NDV-induced immunogenic cell death in prostate cancer cells. Wang X; Shao X; Gu L; Jiang K; Wang S; Chen J; Fang J; Guo X; Yuan M; Shi J; Ding C; Meng S; Xu Q J Cell Mol Med; 2020 Apr; 24(7):4286-4297. PubMed ID: 32100392 [TBL] [Abstract][Full Text] [Related]
13. Autophagy inhibition suppresses Newcastle disease virus-induced cell death by inhibiting viral replication in human breast cancer cells. Rozilah MI; Yusoff K; Chia SL; Ismail S Virology; 2024 Feb; 590():109957. PubMed ID: 38100982 [TBL] [Abstract][Full Text] [Related]
14. Newcastle disease virus: a promising agent for tumour immunotherapy. Zhao L; Liu H Clin Exp Pharmacol Physiol; 2012 Aug; 39(8):725-30. PubMed ID: 22211810 [TBL] [Abstract][Full Text] [Related]
15. Construction of recombinant Newcastle disease virus Italien strain for oncolytic virotherapy of tumors. Wei D; Sun N; Nan G; Wang Y; Liu HQ; Peeters B; Chen ZN; Bian H Hum Gene Ther; 2012 Jul; 23(7):700-10. PubMed ID: 22372930 [TBL] [Abstract][Full Text] [Related]
16. Oncolytic effect of Newcastle disease virus is attributed to interferon regulation in canine mammary cancer cell lines. Santos MR; Xavier PLP; Pires PRL; Rochetti AL; Rosim DF; Scagion GP; de Campos Zuccari DAP; Munir M; Ferreira HL; Fukumasu H Vet Comp Oncol; 2021 Sep; 19(3):593-601. PubMed ID: 33871162 [TBL] [Abstract][Full Text] [Related]
17. Newcastle disease virus as an oncolytic agent. Ravindra PV; Tiwari AK; Sharma B; Chauhan RS Indian J Med Res; 2009 Nov; 130(5):507-13. PubMed ID: 20090097 [TBL] [Abstract][Full Text] [Related]
18. Oncolytic Newcastle disease virus as a prospective anti-cancer therapy. A biologic agent with potential to break therapy resistance. Schirrmacher V Expert Opin Biol Ther; 2015; 15(12):1757-71. PubMed ID: 26436571 [TBL] [Abstract][Full Text] [Related]
19. A Novel Chimeric Oncolytic Virus Vector for Improved Safety and Efficacy as a Platform for the Treatment of Hepatocellular Carcinoma. Abdullahi S; Jäkel M; Behrend SJ; Steiger K; Topping G; Krabbe T; Colombo A; Sandig V; Schiergens TS; Thasler WE; Werner J; Lichtenthaler SF; Schmid RM; Ebert O; Altomonte J J Virol; 2018 Dec; 92(23):. PubMed ID: 30232179 [TBL] [Abstract][Full Text] [Related]
20. Combined therapy of oncolytic Newcastle disease virus and rhizomes extract of Rheum ribes enhances cancer virotherapy in vitro and in vivo. Al-Shammari AM; Jalill RDA; Hussein MF Mol Biol Rep; 2020 Mar; 47(3):1691-1702. PubMed ID: 31970625 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]